FindTrial
Sign In

Efficacy and safety of silodosin on lower urinary tract symptoms (LUTS) in patients with Parkinson's disease

Efficacy and safety of silodosin on lower urinary tract symptoms (LUTS) in patients with Parkinson's disease - Efficacy and safety of silodosin on lower urinary tract symptoms (LUTS) in patients with Parkinson's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000008138
Enrollment
100
Registered
2012-07-01
Start date
2012-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Silodosin 8mg BID

Sponsors

Juntendo University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Male Parkinson's disease patients 2) IPSS>=8 and QOL>=3 3) Patients who accepted to attend in this study with informed consent

Exclusion criteria

Exclusion criteria: Patients who 1) is taking other alpha 1-blockers (Harnal, Flivas), or who cannot do washout taking these drugs 2) had taken anti-androgens or 5 alpha-reductase inhibitors 6 months before the informed consent 3) cannot quit concomitant medications. 4) Cannot record subjective symptoms because of dementia etc. (23>=MMSE) 5) have had surgical treatment such as TURP, thermo thrapy, HoLEP etc. 6) primary physician judged as inadequate to entry in this study

Design outcomes

Primary

MeasureTime frame
Changes in IPSS total score before and after administration of silodosin—

Secondary

MeasureTime frame
QOL score, OABSS, Blood pressure, Adverse events—

Countries

Japan

Contacts

Public ContactGenko Oyama

Juntendo University School of Medicine Department of Neurology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026